Microtubules (MTs) are cytoskeletal elements with a wide range of cellular functions. MTs are not only interesting from a fundamental perspective but are also clinically relevant, in part because they are the targets of so-called MT-active agents (MTAs) that are used successfully in the clinic to combat cancer. We have developed methods to produce and purify functional mammalian tubulin dimers. Here, we propose to use our unique biotechnological expertise for the large-scale production of tubulin isotypes and selected MT-associated proteins. Recombinant tubulins will also serve to generate novel and unique antibodies against different MT conformations.
Reagents and methods are commercially interesting as they will allow researchers and companies to address fundamental and clinical questions of MT behaviour.